輝瑞 CEO 否認會允許在中國生產 Paxlovid 仿製版藥，稱其不是窮國

來源: 三河匹夫 於 2023-01-10 16:23:14 [] [舊帖] [給我悄悄話] 閱讀數 : (16943 bytes)
本帖於 2023-01-10 16:24:33 時間, 由普通用戶 三河匹夫 編輯
 
Vandana Singh
·1 min read
 
 
In this article:
  • Albert Bourla
    Greek-American pharmaceutical executive
 
 

  • Pfizer Inc (NYSE: PFE) CEO Albert Bourla rebuffed reports saying the company is in talks with Chinese authorities to license a generic version of its Covid-19 treatment Paxlovid.

  • Bourla speaking at JPMorgan's healthcare conference, said, "We are not in discussions. We have an agreement already for local manufacturing of Paxlovid in China. So we have a local partner that will make Paxlovid for us, and then we will sell it to the Chinese market."

  • Related: New Oral COVID-19 Antiviral Might Be Better Than Pfizer's Paxlovid With Faster Recovery, Fewer Side Effects, Data Shows.

  • Bourla said the company shipped thousands of Paxlovid courses in 2022 to China and, in the past couple of weeks, had increased that to millions.

  • Concurrently, China's Healthcare Security Administration (NHSA) declined to include Paxlovid in a national reimbursement list that would have allowed patients to get it at a lower price throughout the country.

  • Bourla added, "So they want it lower than the lowest of the middle, and we didn't agree. They are the second-highest economy in the world. And I don't think that they should pay less than Salvador, right, which is a poor country"..."We will continue with the private market in China, which is significant."

  • Price Action: PFE shares are up 0.10% at $48.44 during the premarket session on the last check Tuesday.

請您先登陸，再發跟帖！